Retraction:

Fariba Poosti^1,5, Ruchi Bansal², Saleh Yazdani², Jai Prakash², Leonie Beljaars³, Jacob van den Born⁴, Martin H. de Borst⁴, Harry van Goor¹, Jan-Luuk Hillebrands^1,* and Klaas Poelstra^3,*

¹Department of Pathology and Medical Biology, Division of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
²Department of Biomaterials Science and Technology, Division of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands
³Department of Pharmacokinetics, Toxicology and Targeting, University of Groningen, Groningen, The Netherlands
⁴Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
⁵Department of Microbiology and Immunology, Laboratory of Molecular Immunology, Rega Institute, KU Leuven, Belgium
^*Share senior authorship

Published: January 24, 2024

Copyright: © 2024 Poosti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: This article contains duplicated images found in a previously published paper. Specifically, images of a-SMA expression and fibronectin expression in Figures 3B and 4A were duplicated from Figures 5C and 6C in [1]. Therefore, with the agreement of all authors, Oncotarget has decided to retract this paper.

REFERENCES

1. Poosti F, Bansal R, Yazdani S, Prakash J, Post E, Klok P, van den Born J, de Borst MH, van Goor H, Poelstra K, Hillebrands JL. Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis. FASEB J. 2015; 29:1029–42. https://doi.org/10.1096/fj.14-258459. [PubMed]

Original article: Oncotarget. 2016; 7:54240–54252. DOI: https://doi.org/10.18632/oncotarget.11095